两次与五次立体定向体部放疗治疗中危前列腺癌:TOFFEE 四项前瞻性试验个体患者数据 Meta 分析
该 Meta 分析汇总四项前列腺立体定向体部放疗(SBRT)前瞻性试验的个体患者数据,比较两次 SBRT(2F-SBRT)与五次 SBRT(5F-SBRT)治疗中危前列腺癌(IR-PC)的疗效与生活质量。199 例符合条件患者中 143 例(72%)接受 5F-SBRT、56 例(28%)接受 2F-SBRT,中位随访 9.4 年。两组生化失败(BCF)与远处转移(DM)累积发生率及泌尿、肠道生活质量均无显著差异,作者认为该结果进一步支持 2F-SBRT 成为 IR-PC 标准治疗选择的潜力。
要点
- 2F-SBRT 组 5 年 BCF 累积发生率为 3.6%(95%CI 0-8.6%),5F-SBRT 组为 6.0%(95%CI 1.8-10.2%),差异无统计学意义(p=0.73)。
- 两组远处转移(DM)累积发生率无显著差异。
- 两组急性和晚期泌尿及肠道生活质量均无差异。
核心结论
- 这是首个前列腺 2F-SBRT 与 5F-SBRT 的前瞻性比较,疗效及泌尿、肠道生活质量均无显著差异。
- 该 Meta 分析进一步支持 2F-SBRT 成为中危前列腺癌标准治疗选择的潜力。
研究设计与样本
- 研究类型为个体患者数据 Meta 分析。
- 数据来源为四项前列腺 SBRT 前瞻性试验,其中 2F-SBRT 与 5F-SBRT 各两项。
- 纳入符合条件的中危前列腺癌患者 199 例,5F-SBRT 组 143 例(72%),2F-SBRT 组 56 例(28%)。
- 中位随访 9.4 年。
- 主要终点为生化失败(BCF)累积发生率,次要终点包括远处转移(DM)累积发生率和患者报告的生活质量(QoL)。
主要发现
- 2F-SBRT 组 5 年 BCF 累积发生率为 3.6%(95%CI 0-8.6%),5F-SBRT 组为 6.0%(95%CI 1.8-10.2%),差异无统计学意义(p=0.73)。
- 两组远处转移(DM)累积发生率无显著差异。
- 两组急性和晚期泌尿及肠道生活质量均无差异。
临床怎么用
- 原文结论指出该 Meta 分析进一步支持 2F-SBRT 成为中危前列腺癌标准治疗选择的潜力。
局限性
- 局限性包括比较为非随机化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Recent randomized controlled trials have demonstrated the efficacy of five-fraction stereotactic body radiotherapy (5F-SBRT) for prostate cancer (PC), but there is no comparative evidence for fewer fractions. We compare outcomes of prostate two-fraction SBRT (2F-SBRT) and 5F-SBRT using prospective data for patients with intermediate-risk (IR) PC. METHODS: This meta-analysis of individual patient data evaluated IR-PC from four prospective trials of prostate SBRT (two trials each of 2F- and 5F-SBRT). The primary endpoint was the cumulative incidence of biochemical failure (BCF). Secondary endpoints included the cumulative incidence of distant metastases (DM) and patient-reported quality of life (QoL). KEY FINDINGS AND LIMITATIONS: Of the 199 patients meeting the eligibility criteria, 143 (72%) were in the 5F-SBRT group and 56 (28%) were in the 2F-SBRT group. Median follow-up was 9.4 years. There was no significant difference in BCF with a 5-year cumulative incidence of 3.6% (95% CI 0-8.6%) in the 2F-SBRT group and 6.0% (95% CI 1.8-10.2%) in the 5F-SBRT group (p = 0.73). There was no significant difference in DM incidence. We found no differences in acute and late urinary or bowel QoL. Limitations include the non-randomized comparison. CONCLUSIONS AND CLINICAL IMPLICATIONS: We report the first prospective comparison of prostate 2F-SBRT and 5F-SBRT. We found no significant difference in efficacy, or in urinary or bowel QoL. This meta-analysis further encourages the potential of 2F-SBRT to be a standard-of-care option for IR PC.
引用
- Udovicich C, Cheung P, Chu W, et al. Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials. Eur Urol Oncol. 2025. PMID: 39904690. doi:10.1016/j.euo.2024.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。